Denosumab versus Zoledronic Acid for Men with Osteoporosis: A Review of Clinical Effectiveness and Guidelines [Internet].

There is a need to determine if there is a preferred non-oral agent to increase bone mineral density (BMD) in men with osteoporosis, particularly for cases when patients have failed on or cannot tolerate oral bisphosphonates, for patients with comorbidities that may affect choice of therapy, or for men with early prostate cancer undergoing androgen-deprivation therapy (ADT). In 2015, denosumab (Prolia) was evaluated by the CADTH Common Drug Review (CDR) for the treatment of osteoporosis in men, but zoledronic acid has not been reviewed by CDR for this indication. The Canadian Drug Expert Committee (CDEC) noted that at the time of the CDR review, there were no direct comparisons of denosumab with other therapeutic agents approved for the treatment of men with osteoporosis. The purpose of this report is to evaluate the comparative clinical effectiveness of denosumab and zoledronic acid for the treatment of men with osteoporosis, including men with non-metastatic prostate cancer who are receiving ADT, and to identify evidence-based guidelines for the use of these agents for these indications.

http://ift.tt/2j199Li